Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Fractyl Health, Inc. Common Stock

GUTS

Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.

Last trade $0.9541
Day change -$0.0377 (-3.80%)
Day range $0.939 – $1.07
Volume 199,855
Market cap $13M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$13.13M
Price / earnings
—
Price / book
-7.89×
Price / sales
—
EV / sales
—
EV / EBITDA
0.04×

Profitability

Earnings per share
-$7.96
Return on assets
-128.88%
Return on equity
6,345.35%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-18.29×
Current ratio
3.15×
Quick ratio
3.15×
Cash ratio
3×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$82.44M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GUTS, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$3K$14K
Cost of revenue$0$0$0$0$0$0$0$7K
Gross profit$0$0$0$0$0$0$3K$7K
Selling, general and administrative$5.28M$5.22M$6.79M$5.24M$4.93M$5.32M$4.93M$4.8M
Research and development$13.81M$15.6M$16.49M$17.46M$21.15M$19.44M$20.28M$19M
Total operating expenses$19.1M$20.82M$23.28M$22.69M$26.08M$24.76M$25.21M$23.8M
Operating income-$19.1M-$20.82M-$23.28M-$22.69M-$26.08M-$24.76M-$25.21M-$23.79M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$25.54M$9.22M-$43.73M-$45.6M-$27.89M-$23.74M-$24.97M-$23.17M
Income taxes$0$0$0$0$0$0$0$0
Net income-$25.54M$9.22M-$43.73M-$45.6M-$27.89M-$23.74M-$24.97M-$23.17M
Net income attributable to common shareholders-$25.54M$9.22M-$43.73M-$45.6M-$27.89M-$23.74M-$24.97M-$23.17M
EBITDA-$18.82M-$20.54M-$23.01M-$22.4M-$25.81M-$24.47M-$24.99M-$23.59M
Basic earnings per share-$1.92$0.72-$3.73-$8.52-$6.84-$5.88-$6.17-$5.76
Diluted earnings per share-$1.92$0.72-$3.73-$8.52-$6.84-$5.88-$6.17-$5.76

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026

Fractyl Health, a clinical-stage metabolic therapeutics company, announced it will report Q3 2026 financial results on November 12, 2026. The company is advancing its lead product Revita, an endoscopic procedural therapy for post-GLP-1 weight maintenance, toward FDA submission. Fractyl has strengthened its patent portfolio and released market research showing substantial patient interest in one-time procedural approaches, with approximately one million U.S. patients monthly discontinuing GLP-1 medications.

GlobeNewswire Inc.

Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS

Pomerantz LLP has filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) and certain officers for alleged securities fraud. The lawsuit claims Defendants made materially false and misleading statements about the efficacy of Revita, their metabolic therapy device, while conducting public offerings in August-September 2025. On January 29, 2026, Fractyl disclosed disappointing six-month data from the REMAIN-1 Midpoint Cohort showing only 4.5% weight regain versus 7.5% in the sham arm, significantly below expectations. The disclosure revealed operational issues at one clinical site compromised study integrity. Following the announcement, Fractyl's stock price plummeted 68.03% on January 29, 2026, and fell an additional 21.37% on January 30, 2026.

GlobeNewswire Inc.

GUTS DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20th

A class action lawsuit has been filed against Fractyl Health, Inc. for allegedly making materially false and misleading statements about its Revita product's effectiveness and clinical trial integrity during the Class Period of January 13, 2025 to January 29, 2026. Investors with losses are urged to contact the law firm before the October 20, 2026 lead plaintiff deadline. Similar lawsuits have also been filed against Taboola.com Ltd., AEVEX Corp., and Coastal Financial Corporation.

GlobeNewswire Inc.

GUTS DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20th

A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that the company made materially false and misleading statements regarding its Revita product's effectiveness and clinical trial integrity. Investors who purchased Fractyl securities between January 13, 2025 and January 29, 2026 have until October 20, 2026 to apply as lead plaintiff.

GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that company executives made materially false and misleading statements regarding the effectiveness of its Revita product and the integrity of clinical trial results. The lawsuit covers investors who purchased Fractyl securities between January 13, 2025 and January 29, 2026. The lead plaintiff deadline is October 20, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 5, 20261-for-12reverse split